Ultrasound Can Read Weight of Fetuses With FGR in Obese Moms

This article originally appeared here.
Share this content:
Ultrasound Can Read Weight of Fetuses With FGR in Obese Moms
Ultrasound Can Read Weight of Fetuses With FGR in Obese Moms

THURSDAY, Dec. 17, 2015 (HealthDay News) -- Sonographic (US) examination can accurately estimate fetal weight, even in overweight and obese women with singleton pregnancies affected by fetal growth restriction (FGR), according to research published in the January issue of the Journal of Clinical Ultrasound.

Fiona Cody, from Rotunda Hospital in Dublin, and colleagues describe the effect of maternal obesity on the accuracy of US in determining the estimated fetal weight (EFW) and perinatal outcome of pregnancies affected by FGR. A total of 1,116 women with nonanomalous singleton pregnancies with an EFW in less than the 10th centile were recruited. The authors determined the accuracy of EFW for women who delivered within two weeks of their latest US scan.

Data were included for 1,074 women with complete records, of whom, 64 percent were normal weight, 24 percent were overweight, and 9 and 3 percent were obese class 1 and 2, respectively. The researchers found that for women in all body mass index (BMI) categories, the EFW determined prior to delivery was within 6 percent of the actual birth weight. Compared to women with a normal BMI, overweight and obese women delivered more often by cesarean section and at earlier gestational ages, resulting in lower birth weights and significantly increased perinatal morbidity and mortality rates.

"US examination is reliable for assessing the weight of fetuses with FGR in overweight women," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths